September 2, 2021 8:14am
Pre-open indications: SELLs into Strength: 3; SELL: 1; BUY: 1; Maintain SELL: 1
If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing.
Never leave an investor uninformed!
Dow futures are UP +0.17% (+60 points), S&P futures are UP +0.19% (+9 point) and NASDAQ futures are UP +0.29% (+45 points)
U.S. stock futures gained slightly on Thursday … point to a higher open
European Markets inched higher,
Asia-Pacific markets overnight, shares were mixed as investors reacted to trade data and corporate news from the region.
Data Docket: weekly initial jobless claims report Thursday and the Labor Department’s nonfarm payrolls report on Friday, which could provide clues on Fed policy
Key jobs data the next two days could dictate trading. On Thursday, weekly jobless claims are expected to fall to 345,000, down from 353,000 in the week prior, according to economists polled by Dow Jones.
Friday brings the big August jobs report, which investors are watching closely to decipher how fast the Federal Reserve will remove easy monetary policy.
Economists predict 720,000 jobs were added in the month, down from 943,000 jobs added in July. On Wednesday, ADP data showed U.S. companies created fewer jobs in August than expected. <CNBC>
If you didn’t know what happen at Tuesday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:
- Wednesday’s evening’s recap: “are we in a goldilocks continuum?” … https://www.regmedinvestors.com/articles/12076
- The Nasdaq closed UP +50.15 points (+0.33%);
- The IBB closed up +1.03% and XBI closed up +1.69%
- Sector volume was LOW with 7 of the 26-upside having higher than the 3-month average volume with very LOW volume of 2 of 7-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -0.37 points or -2.25% at 16.11
- Wednesday’s percentage (%) of the 27-upside were +0.11% (BLUE) to +16.83% (BLCM) while the 7-downside -0.52% (KDNY) to -10.71% (BSTG);
- September, 1positive close
- August - 12 positive and 10 negative close
- July: 6 positives, 1 holiday and 15 negative closes
Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542 … to date:
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trade with the “pump/promote”?
Biostage (BSTG) closed down again -$0.36 to $3.00 after Tuesday’s -$0.44 to $3.36 with 11,564 shares traded after Monday’s +$0.75 to $3.80 with 25,607 shares traded after Friday’s +$0.45 to $3.05 with 19,982 share traded, Thursday’s +$0.39 with 3,137 shares traded, Wednesday’s +$0.16 with 18,472 shares traded and last Tuesday’s +$0.28 with 10,590 shares traded and the previous Monday’s +$0.68 to $1.89 with 38,354 shares traded.
Question#1: Being able to trade a stock doesn't mean it is worth the share price; an equity that has WHAT is BSTG’s value proposition, after all the share price pumping – NO clinical trial?
Questiob#2: WHAT is the end game of “pumping” the share price as the float is MINIMAL compared to the ever-OUTSTANDING shares? WHERE is the SEC?
MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.
SELL into Strength (for profit):
Intellia Therapeutics (NTLA) closed up +$4.51 after Tuesday’s+$6.58 after Monday’s down -$6.05 with a positive +$0.86 or +0.52% pre-market indication,
CRISPR Therapeutics (CRSP) closed up again +$1.41 after Tuesday’s +$4.24 and has a positive +1.52 or 1.29% pre-market indication,
Editas Medicine (EDIT) closed up +$3.07 after Tuesday’s +$1.79 and has a positive +$1.33 or +1.99% pre-market indication,
BUY from SELL:
Mesoblast (MESO) closed down again -$0.48 after Tuesday’s -$0.79 and has a positive +$0.06 or +0.99% pre-market indication,
BioLife Solutions (BLFS) closed up again +$2.14 after Tuesday’ +$0.04 and has a negative -$0.50 or -0.83% pre-market indication as it seeks to register the share from the latest acquisition.
The BOTTOM LINE: a long holiday is coming and with the market, some will exit early and let stocks ride
When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started
Investors should take short-term profits to cash-up for coming drifts!
Some earnings’ Reports Outstanding:
- Applied Genetic Technologies (AGTC) – 9/8 reporting, Mesoblast (MESO) – still trying to access, Pluristem (PSTI) and ReNeuron (RENE.L)
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.